News & Media

Press release 2015/12/21 Regulatory

Medivir announces that development of the HCV nucleotide polymerase inhibitor AL-704 was terminated by Janssen

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the development of AL-704 (also known as JNJ-54257099) has been...

Press release 2015/11/20 Regulatory

MEDIVIR AB – INTERIM REPORT, THIRD QUARTER 2015

Financial summary Third quarter 2015 (2014) Net turnover totalled SEK 111.5 million (617.8 m), of which SEK 69.0 million (516.4 m)...

Press release 2015/11/17 Regulatory

Medivir terminates the ADAM8 inhibitor project for pancreatic cancer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that it will terminate its ADAM8 inhibitor project for pancreatic cancer....

Press release 2015/10/16 Regulatory

Medivir announces that Janssen has started a phase IIa study to evaluate the effect of simeprevir in combination with odalasvir and AL-335

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen),...

Press release 2015/10/13 Regulatory

OLYSIO® sales during the third quarter 2015

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the global third quarter net sales of OLYSIO® (simeprevir) amounted to...

Press release 2015/09/16

Medivir to merge Research and Development and implement changes within the management group

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that, as the next step in the company's optimisation process, its...

Press release 2015/08/20 Regulatory

MEDIVIR AB – INTERIM REPORT, SECOND QUARTER 2015

Financial summary Second quarter 2015 (2014) Net turnover totalled SEK 245.8 million (564.0 m), of which SEK 165.6 million (500.7 m)...

Press release 2015/08/03 Regulatory

Medivir announces that Janssen has started a phase I study to evaluate the effect of simeprevir and odalasvir on AL-335 pharmacokinetics

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen)...

Press release 2015/07/29 Regulatory

Medivir announces start of a phase I clinical trial of the nucleotide polymerase inhibitor AL-704 for treatment of hepatitis C

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces the start of a phase I clinical trial with AL-704, also...

Press release 2015/07/24 Regulatory

Medivir announces that Janssen submitted supplemental New Drug Application to U.S. FDA for OLYSIO® (simeprevir) in combination with sofosbuvir

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Products, LP (Janssen ), has submitted a supplemental New...

Press release 2015/07/14 Regulatory

OLYSIO® sales during the second quarter 2015

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the global second quarter net sales of OLYSIO® (simeprevir) amounted to...

Press release 2015/06/30 Regulatory

Medivir announces the first cancer project derived from its in-house nucleotide platform

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces a new discovery project for a cancer indication, a liver targeted...